BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32410009)

  • 1. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
    Mariya T; Kubo T; Hirohashi Y; Yanagawa J; Tabuchi Y; Matsuo K; Furumura K; Morita R; Nakatsugawa M; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Torigoe T
    Med Mol Morphol; 2021 Mar; 54(1):14-22. PubMed ID: 32410009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
    Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
    Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features of 50 mismatch repair (MMR)-deficient endometrial carcinomas, tested by immunohistochemistry: A single institutional feasibility study, India.
    Rekhi B; Menon S; Deodhar KK; Ghosh J; Chopra S; Maheshwari A
    Ann Diagn Pathol; 2020 Aug; 47():151558. PubMed ID: 32619922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.
    Glaire MA; Ryan NA; Ijsselsteijn ME; Kedzierska K; Obolenski S; Ali R; Crosbie EJ; Bosse T; de Miranda NF; Church DN
    J Pathol; 2022 Jul; 257(3):340-351. PubMed ID: 35262923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression.
    Stewart CJR; Pearn A; Pachter N; Tan A
    Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival with an intact DNA mismatch repair system in endometrial cancer.
    Cohn DE; Frankel WL; Resnick KE; Zanagnolo VL; Copeland LJ; Hampel H; Kelbick N; Morrison CD; Fowler JM
    Obstet Gynecol; 2006 Nov; 108(5):1208-15. PubMed ID: 17077244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
    Park JH; Powell AG; Roxburgh CS; Horgan PG; McMillan DC; Edwards J
    Br J Cancer; 2016 Mar; 114(5):562-70. PubMed ID: 26859693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
    Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
    de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
    Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Khushman MM; Toboni MD; Xiu J; Manne U; Farrell A; Lou E; Shields AF; Philip PA; Salem ME; Abraham J; Spetzler D; Marshall J; Jayachandran P; Hall MJ; Lenz HJ; Sahin IH; Seeber A; Powell MA
    Clin Cancer Res; 2024 May; 30(9):1906-1915. PubMed ID: 38350001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon.
    Kubo T; Hirohashi Y; Matsuo K; Sonoda T; Sakamoto H; Furumura K; Tsukahara T; Kanaseki T; Nakatsugawa M; Hirano H; Furuhata T; Takemasa I; Hasegawa T; Torigoe T
    Anticancer Res; 2017 Mar; 37(3):1289-1295. PubMed ID: 28314294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.